AVBP earnings date and last-quarter result: next report 2026-08-10, last quarter miss, P/E -8.62. Updated 2026-07-23.
ArriVent BioPharma (AVBP) Research Hub
ArriVent BioPharma (AVBP) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 15.36 USD (-26.86%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -8.62, market cap 1.40B. This hub links to the full technical, earnings and options research available for AVBP.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 15.36 USD (-26.86%) |
| 52-week range | 11.36 USD – 35.83 USD |
| Trend regime | Range |
| 14-day RSI | 51 (Neutral) |
| Trailing P/E | -8.62 |
| Market cap | 1.40B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for AVBP
Covered Call on AVBP: how it works, illustrative setup around the real 15.36 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on AVBP: how it works, illustrative setup around the real 15.36 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on AVBP: how it works, illustrative setup around the real 15.36 USD price, max profit/loss, breakeven and when to use it. Educational.
AVBP technical analysis: range, last 15.36 USD, RSI 51, 52w range 11.36 USD–35.83 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is AVBP in?
ArriVent BioPharma (AVBP) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is AVBP in an uptrend or downtrend?
As of 2026-10-26, AVBP is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is AVBP's trailing P/E ratio?
AVBP's trailing P/E is -8.62, with a market cap of 1.40B. See the earnings research page for full valuation detail.
When does AVBP next report earnings?
AVBP is next scheduled to report earnings on 2026-08-10.